explore -WSS

explore

author：entertainment 2025-09-30 08:00:51 - browse：799

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Hospitals use virtual reality to design more inclusive rooms for kids

WSS

Amazon expands telehealth clinic nationwide

What to expect as Trump is arraigned on his Jan 6. indictment

What to expect as Trump is arraigned on his Jan 6. indictment

Amazon expands telehealth clinic nationwide

Ohioans vote in high

‘Oppenheimer’ and the risks of AI in health care

focus

explore

knowledge

How to save PrEP access — and even expand it

Lawsuit alleges UnitedHealth Group unit illegally denied claims

The cancer drug shortage isn’t new — and neither are the solutions

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Medical records are filled with copy

‘The Bear’ and hospitality in hospitals

BioMarin wins approval for gene therapy to treat hemophilia A

The high personal cost of affirmative action for Black doctors

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

‘The Bear’ and hospitality in hospitals

Wikipedia

New safety details link Apellis eye drug to rare cases of blindness

More regulation could be coming for drug ads

EQRx, failed developer of low

Scientists inch closer to single

What the US credit downgrade means for the economy, your finances

New safety details link Apellis eye drug to rare cases of blindness

leisure time

leisure time

hotspot

focus